Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 9Neoplasms 6Lung Neoplasms 5Neoplasm Metastasis 4Colorectal Neoplasms 4Breast Neoplasms, Male 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Recurrence 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Inflammatory Breast Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Solid Tumor 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms, Basal Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced NUT Carcinoma × Taxes × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡